Neuren Pharmaceuticals (NEU) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic focus and business overview

• Focused on neurodevelopmental disorders with significant unmet needs, targeting syndromes caused by genetic mutations that impact multiple aspects of life, including Rett, Fragile X, Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes.

• Utilizes IGF-1 analogs for oral liquid therapies addressing impaired neuronal communication.

• Two main products: Daybue (trofinetide), a commercialized drug for Rett syndrome, and NNZ-2591, an investigational drug in clinical trials for multiple syndromes.

• Orphan drug indications allow for favorable pricing, regulatory concessions, and extended exclusivity.

• Emphasizes a multi-indication platform approach for NNZ-2591.

Pipeline progress and clinical results

• NNZ-2591 shows positive Phase II results in Phelan-McDermid, Pitt-Hopkins, and Angelman syndromes, with over 80% of patients improved per physicians and 66–85% per caregivers.

• Most advanced clinical programs are in PMS and PTHS; positive FDA End of Phase 2 meeting for PMS.

• Phase II trials demonstrate safety, tolerability, and consistent efficacy across multiple syndromes.

• Preparing for phase III trial in Phelan-McDermid syndrome, pending FDA alignment on efficacy endpoints.

• Advancing non-clinical studies in additional undisclosed indications.

Daybue (trofinetide) performance and growth

• Approved for Rett syndrome in March 2023, with a highly successful launch and rapid uptake in the U.S.; over 1,600 patients treated.

• 2023 sales reached $177 million, growing to $340–$350 million in 2024.

• Second wave of growth targeted at patients outside centers of excellence, supported by a 30% increase in sales force and direct-to-consumer campaigns.

• Global expansion underway: approval in Canada, regulatory filing in Europe, and plans for Japan trial.

• EU marketing application submitted, with potential approval in Q1 2026 and managed access program starting Q2 2025.